Mechanisms of Mitochondrial Iron Uptake: New Therapeutic Targets in Hepatotoxicity
线粒体铁摄取机制:肝毒性的新治疗靶点
基本信息
- 批准号:10597049
- 负责人:
- 金额:$ 45.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AcetaminophenAddressAffectAffinityAreaBindingBinding SitesBioenergeticsBiological AssayBiologyCationsCell Membrane PermeabilityCell membraneCellsCitratesComplexConfocal MicroscopyCore ProteinDNA DamageDataDivalent CationsEndosomesFerritinGenerationsGenetic ModelsHemeHepatocyteHepatotoxicityHomeostasisHydroxyl RadicalImageIn VitroInner Limiting MembraneInner mitochondrial membraneInterventionIronIron OverloadKineticsKnock-outKnowledgeLiver diseasesLysosomesMeasurementMediatingMembraneMembrane PotentialsMembrane ProteinsMitochondriaMitochondrial ProteinsModelingMolecularMutationOxidation-ReductionOxidative StressPathway interactionsPermeabilityPhysiologicalPlayPredispositionProcessProtein IsoformsProteinsReactionReactive Oxygen SpeciesRoleSLC11A2 geneSulfurTimeToxic effectTransition Elementsacetaminophen-induced liver injurycalcium uniporterclinically relevantcofactorexperimental studyhepatocellular injuryin vivoinnovationinsightiron metabolismmitochondrial dysfunctionmitochondrial membranenew therapeutic targetnovelnovel therapeuticspreventsuperresolution microscopytooluptake
项目摘要
Iron is a transition metal that exists in two pools within cells. Chelatable iron comprises free iron and iron
loosely bound to anionic metabolites like ATP and citrate, whereas non-chelatable iron is tightly bound to ferritin,
heme and iron-sulfur clusters. Redox active chelatable iron promotes oxidative stress by catalyzing the Fenton
reaction, which produces highly reactive hydroxyl radicals that damage DNA, proteins and membranes. Much
evidence implicates mitochondrial iron as an important contributor to toxicity, but the molecular pathways of
mitochondrial iron uptake are incompletely understood. Current dogma is that mitoferrin (Mfrn1 and 2), a
mitochondrial inner membrane protein, is responsible for mitochondrial iron transport. However, studies from 45
years ago show that the classical electrogenic mitochondrial calcium uniporter (MCU) complex also catalyzes
uptake of Fe2+ but not Fe3+ driven by the mitochondrial membrane potential, a conclusion supported by our own
studies in intact and permeabilized cells. Our preliminary pull-down, Duolink and super-resolution microscopy
studies show a physical association of Mfrn2, the predominant isoform in non-erythroid cells, with MCU, the core
protein of the MCU complex. This brings us to the fundamental questions to be addressed by this proposal: 1)
Do mitochondria accumulate iron via two independent pathways: a non-electrogenic pathway mediated by Mfrn
and an electrogenic pathway catalyzed by MCU? 2) Alternatively do Mfrn and the molecular components of MCU
exist within a single complex mediating both Fe2+ and Ca2+ uptake? 3) Is Mfrn an exchanger, such as an
Fe2+/Na+(H+) exchanger in analogy to Ca2+/Na+, Mg2+/Na+, and Na+/H+ exchangers? 4) How do MCU and Mfrn,
as well as divalent metal transporter 1 (DMT1), contribute to hepatotoxicity? In Aim 1, we will characterize
mitochondrial Fe2+ uptake and exchange in plasma membrane-permeabilized wildtype (WT), MCU knockout (KO)
and Mfrn1/2 double KO (DKO) hepatocytes. Aim 2 will identify interactions of Mfrn2 with other proteins using an
unbiased enrichment-mass spectrometric (AE-MS) approach, DuoLink and super-resolution microscopy to
establish whether or not Mfrn2 and MCU are authentic binding partners and also to identify associations of Mfrn2
with other novel partners. Aim 3 will assess how targeted mutations affect susceptibility to acetaminophen
(APAP) toxicity, which is mediated by iron. Specifically, we will determine how deficiencies of MCU, Mfrn2 and
DMT1 affect APAP-induced mitochondrial dysfunction and hepatocellular killing in vitro and in vivo. We expect
these studies to define the specific roles of MCU, Mfrn2 and DMT1 in this clinically relevant model of
hepatocellular injury. The concept that Mfrn and MCU are both essential for both mitochondrial Fe2+ uptake and homeo-stasis is novel, innovative and paradigm-shifting. The project will provide insights into an unexplored area of
biology and fill an important gap in our understanding of the pathways involved in mitochondrial iron uptake and
iron-dependent toxicities. Better understanding of the process will eventually lead to more specific interventions
against hepatic diseases promoted by iron overload.
铁是一种过渡金属,存在于细胞内的两个池中。可螯合铁包括游离铁和铁
与阴离子代谢物如ATP和柠檬酸盐松散结合,而不可螯合的铁与铁蛋白紧密结合,
血红素和铁硫簇。氧化还原活性螯合铁通过催化芬顿促进氧化应激
反应,产生高活性的羟基自由基,破坏DNA,蛋白质和膜。多
有证据表明线粒体铁是毒性的重要贡献者,但线粒体铁的分子途径
线粒体铁摄入还不完全清楚。目前的教条是,线粒体铁蛋白(Mfrn 1和2),
线粒体内膜蛋白,负责线粒体铁转运。研究显示,45
多年前的研究表明,经典的产电线粒体钙单向转运体(MCU)复合物也催化
线粒体膜电位驱动Fe 2+而不是Fe 3+的摄取,这一结论得到了我们自己的支持。
对完整和透化细胞的研究。我们初步的下拉式、Duolink和超分辨率显微镜
研究表明,Mfrn 2(非红系细胞中的主要同种型)与MCU(核心细胞)之间存在物理联系。
MCU复合物的蛋白质。这就引出了本提案所要解决的基本问题:1)
线粒体是否通过两条独立的途径积累铁:一条由Mfrn介导的非产电途径
和MCU催化的产电途径2)或者做Mfrn和MCU的分子组分
存在于一个单一的复杂介导的Fe 2+和Ca 2+的吸收?3)Mfrn是一种交换器,例如
Fe 2 +/Na+(H+)交换剂类似于Ca 2 +/Na+、Mg 2 +/Na+和Na+/H+交换剂?4)MCU和Mfrn如何,
以及二价金属转运蛋白1(DMT 1),有助于肝毒性?在目标1中,我们将描述
质膜透性野生型(WT)、MCU敲除(KO)中的线粒体Fe 2+摄取和交换
和Mfrn 1/2双KO(DKO)肝细胞。目的2将使用一种新的方法来鉴定Mfrn 2与其他蛋白质的相互作用。
无偏富集质谱(AE-MS)方法,DuoLink和超分辨率显微镜,
确定Mfrn 2和MCU是否是真实的结合配偶体,并且还鉴定Mfrn 2的关联
与其他新的合作伙伴。目标3将评估靶向突变如何影响对乙酰氨基酚的易感性
(APAP)毒性,其由铁介导。具体来说,我们将确定MCU、Mfrn 2和
DMT 1影响APAP诱导的线粒体功能障碍和肝细胞杀伤在体外和体内。我们预计
这些研究旨在定义MCU、Mfrn 2和DMT 1在这种临床相关模型中的具体作用,
肝细胞损伤Mfrn和MCU对于线粒体Fe 2+摄取和稳态都是必不可少的概念是新颖的、创新的和范式转变的。该项目将提供一个未探索的领域的见解,
填补了我们对线粒体铁摄取途径的理解中的一个重要空白,
铁依赖性毒性更好地理解这一过程将最终导致更具体的干预措施
对抗由铁超载引起的肝脏疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John J Lemasters其他文献
Ischemic preconditioning attenuates acute lung injury after partial liver transplantation
缺血预处理减轻部分肝移植后的急性肺损伤
- DOI:
- 发表时间:
2018 - 期刊:
- 影响因子:0
- 作者:
Qinlong Liu;Hasibur Rehman;Yasodha Krishnasamy;John J Lemasters;Zhi Zhong - 通讯作者:
Zhi Zhong
John J Lemasters的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John J Lemasters', 18)}}的其他基金
Mechanisms of Mitochondrial Iron Uptake: New Therapeutic Targets in Hepatotoxicity
线粒体铁摄取机制:肝毒性的新治疗靶点
- 批准号:
10210670 - 财政年份:2021
- 资助金额:
$ 45.62万 - 项目类别:
Mechanisms of Mitochondrial Iron Uptake: New Therapeutic Targets in Hepatotoxicity
线粒体铁摄取机制:肝毒性的新治疗靶点
- 批准号:
10349589 - 财政年份:2021
- 资助金额:
$ 45.62万 - 项目类别:
Mitochondrial depolarization, mitophagy, and mitochondrial DAMPs in ALD
ALD 中的线粒体去极化、线粒体自噬和线粒体 DAMP
- 批准号:
10155373 - 财政年份:2018
- 资助金额:
$ 45.62万 - 项目类别:
Mitochondrial depolarization, mitophagy, and mitochondrial DAMPs in ALD
ALD 中的线粒体去极化、线粒体自噬和线粒体 DAMP
- 批准号:
9920650 - 财政年份:2018
- 资助金额:
$ 45.62万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 45.62万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 45.62万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 45.62万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 45.62万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 45.62万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 45.62万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 45.62万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 45.62万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 45.62万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 45.62万 - 项目类别:
Research Grant